This study aimed to assess the frequency of hormone therapy-related side effects, their impact on quality of life (QoL), and specifically the behavior of reporting symptoms to physicians in adult women diagnosed with HR+ breast cancer and undergoing adjuvant hormone therapy (tamoxifen or aromatase inhibitor ± OFS). This evidence concerns the gene CYP19A1 and breast cancer.